Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 5,229 matching trials from the live ClinicalTrials.gov search.
Conditions
Discogenic Pain
Interventions
Bone Marrow Concentrate, Placebo
Other
Lead sponsor
APM Spine and Sports Physicians
Other
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Virginia Beach, Virginia
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Conditions
Asthma
Interventions
Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 84 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Newport Beach, California • Westminster, California • Winter Park, Florida + 6 more
Completed Phase 2Phase 3 Interventional Results available

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

NCT00755079
Conditions
Spinal Cord Injury
Interventions
extended release beta-2 adrenergic agonist, placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Interventions
Avatrombopag, Matching Placebo
Drug
Lead sponsor
Hanny Al-Samkari, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Portland, Oregon + 1 more
Conditions
Age-Related Macular Degeneration
Interventions
Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery
Biological · Drug · Procedure
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Onychomycosis
Interventions
NVXT topical, Placebo (Vehicle) Topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 6-Month Formulation

NCT03345342
Conditions
Schizophrenia
Interventions
PP6M, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Rogers, Arkansas • Anaheim, California • Costa Mesa, California + 21 more
Not listed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Intranasal Dexmedetomidine

NCT02985697
Conditions
Safety and Efficacy of Intranasal Dexmedetomidine
Interventions
Dexmedetomidine, Midazolam Hydrochloride, Nitrous Oxide
Drug
Lead sponsor
Bon Secours Pediatric Dental Associates
Other
Eligibility
3 Years to 6 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Multiple Sclerosis
Interventions
4.5 mg Naltrexone, Naltrexone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 86 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Francisco, California
Conditions
Asthma Acute
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Palo Alto, California • Valencia, California • Wilmington, Delaware + 17 more
Conditions
Hypertension
Interventions
LCZ696, Olmesartan, Placebo of LCZ696, Placebo of Olmesartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Birmingham, Alabama • Fair Oaks, California • Hawaiian Gardens, California + 18 more
Conditions
Chronic Constipation, Methanogenesis
Interventions
Lubiprostone, Lubiprostone Control
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Iowa City, Iowa • Salt Lake City, Utah
Conditions
Seasonal Allergic Rhinitis
Interventions
Epinastine Nasal Spray
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
571 participants
Timeline
2006 – 2007
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Placebo Oral Tablet, GKT137831
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
Conditions
Parkinson's Disease
Interventions
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD
Combination Product · Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Conditions
Plantar Fibromatosis
Interventions
EN3835, Placebo
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Mesa, Arizona • Tucson, Arizona • Bakersfield, California + 37 more
Conditions
Cognitive Disorders, HIV Infections
Interventions
Thioctic acid, Selegiline hydrochloride
Drug
Lead sponsor
The Dana Foundation
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York
Conditions
Multiple Sclerosis
Interventions
Speed of Processing Training (SPT), Placebo Control
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
West Orange, New Jersey
Conditions
Post Traumatic Stress Disorder
Interventions
3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE)
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Conditions
Narcolepsy
Interventions
sodium oxybate
Drug
Lead sponsor
Orphan Medical
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
37
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 31 more
Conditions
Postural Tachycardia Syndrome
Interventions
Stellate ganglion block, Sham injection of saline, Ropivacaine, Normal saline
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Stanford, California
Conditions
Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more